Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Core Insights - Adial Pharmaceuticals will present at the ThinkEquity Conference on October 30, 2024, focusing on innovations in addiction treatment [1][2] - The company's lead product, AD04, is a genetically targeted therapy for Alcohol Use Disorder (AUD) and has shown promising results in clinical trials [4] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing therapies for addiction and related disorders [4] - The lead investigational drug, AD04, is a serotonin-3 receptor antagonist aimed at treating AUD in heavy drinkers, with potential applications for other addictive disorders [4] Conference Details - Cary Claiborne, CEO of Adial, will present at 8:30 a.m. ET, with one-on-one investor meetings scheduled throughout the day [2] - The ThinkEquity Conference serves as a platform for institutional investors and industry professionals to connect and discuss financial strategies [3]